BioAge Labs (NASDAQ:BIOA) Sets New 1-Year High – Still a Buy?

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $25.80 and last traded at $25.4950, with a volume of 37788 shares changing hands. The stock had previously closed at $25.10.

Analyst Ratings Changes

Several analysts have commented on the stock. Needham & Company LLC began coverage on shares of BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Roth Mkm initiated coverage on BioAge Labs in a research note on Wednesday, May 27th. They issued a “buy” rating and a $36.00 target price on the stock. Finally, BTIG Research began coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

BioAge Labs Stock Performance

The company has a 50-day moving average of $18.68 and a 200-day moving average of $18.34. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -10.47 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. As a group, analysts anticipate that BioAge Labs, Inc. will post -2.68 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

A number of institutional investors have recently modified their holdings of BIOA. Janus Henderson Group PLC boosted its position in shares of BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after buying an additional 1,685,063 shares during the period. Octagon Capital Advisors LP lifted its stake in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after acquiring an additional 150,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after acquiring an additional 93,694 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of BioAge Labs during the 4th quarter worth approximately $13,892,000. Finally, Geode Capital Management LLC raised its holdings in shares of BioAge Labs by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after purchasing an additional 28,646 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.